甲状腺交界性肿瘤诊断和预后相关分子标志物的研究进展Research progress in diagnosis- and prognosis-related molecular markers of borderline thyroid tumor

doi:10.13481/j.1671-587X.20210334

Abstract

CLC Number:

R736.1

Figures/Tables 1

References

1	LLOYD R，OSAMURA R，KLOPPEL G，et al．WHO classification of tumours： pathology and genetics of tumours of endocrine organs［M］．4th ed．Lyon： IARC Press，2017．
2	AKAISHI J， KONDO T， SUGINO K， et al. Prognostic impact of the Turin criteria in poorly differentiated thyroid carcinoma［J］. World J Surg， 2019， 43（9）： 2235-2244.
3	ZHU Y， LI Y Q， JUNG C K， et al. Histopathologic assessment of capsular invasion in follicular thyroid neoplasms-an observer variation study［J］. Endocr Pathol， 2020， 31（2）： 132-140.
4	罗定远，廖健伟. 甲状腺癌基因检测与临床应用广东专家共识（2020版）［J］. 中华普通外科学文献（电子版）， 2020， 14（3）： 161-168.
5	DE MATOS L L，BDEL GIGLIO A， MATSUBAYASHI C O，et al. Expression of CK-19， galectin-3 and HBME-1 in the differentiation of thyroid lesions：systematic review and diagnostic meta-analysis［J］. Diagn Pathol， 2012， 7： 97.
6	BALOCH Z， METE O， ASA S L. Immunohistochemical biomarkers in thyroid pathology［J］. Endocr Pathol， 2018， 29（2）： 91-112.
7	HOFMAN V， LASSALLE S， BONNETAUD C，et al.Thyroid tumours of uncertain malignant potential： frequency and diagnostic reproducibility［J］. Virchows Arch， 2009， 455（1）： 21-33.
8	冯耀霞，张岚，李群锋，等. 恶性潜能未定的高分化甲状腺肿瘤中CK19、Galectin-3、HBME-1和TPO的表达及意义［J］. 实用肿瘤杂志， 2017， 32（4）： 362-366.
9	ZHU H， QI J P， WANG Y W， et al. Hyalinizing trabecular tumor and papillary carcinoma of the thyroid［J］. Chin Med J （Engl）， 2010， 123（20）： 2832-2835.
10	SUNG S Y， SHEN H Y， HSIEH C B， et al. Hyalinizing trabecular tumor of thyroid： does frozen section prevent unnecessarily aggressive operation？ Six new cases and a literature review［J］. J Chin Med Assoc， 2014， 77（11）： 573-577.
11	任配友，刘嘉，王培松，等. 甲状腺透明变梁状肿瘤研究进展［J］. 中国肿瘤临床， 2015， 42（15）： 774-777.
12	HIROKAWA M， SHIMIZU M， MANABE T， et al. Hyalinizing trabecular adenoma of the thyroid： its unusual cytoplasmic immunopositivity for MIB₁［J］. Pathol Int， 1995， 45（5）： 399-401.
13	TAKADA N， HIROKAWA M， OHBAYASHI C， et al. Re-evaluation of MIB-1 immunostaining for diagnosing hyalinizing trabecular tumour of the thyroid： semi-automated techniques with manual antigen retrieval are more accurate than fully automated techniques［J］. Endocr J， 2018， 65（2）： 239-244.
14	FU G D， POLYAKOVA O， MACMILLAN C， et al. Programmed death-ligand 1 expression distinguishes invasive encapsulated follicular variant of papillary thyroid carcinoma from noninvasive follicular thyroid neoplasm with papillary-like nuclear features［J］. EBioMedicine， 2017， 18： 50-55.
15	程若川,杨婷婷.2016版中国甲状腺微小乳头状癌诊断与治疗专家共识解读[J].中国实用内科杂志,2019,39(4):351-357.
16	JINIH M， FOLEY N， OSHO O， et al. BRAF^V600E mutation as a predictor of thyroid malignancy in indeterminate nodules： a systematic review and meta-analysis［J］. Eur J Surg Oncol， 2017， 43（7）：1219-1227.
17	BYCHKOV A， JUNG C K， LIU Z Y， et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features in Asian practice： perspectives for surgical pathology and cytopathology［J］. Endocr Pathol， 2018， 29（3）： 276-288.
18	ZHAO L N， DIAS-SANTAGATA D， SADOW P M， et al. Cytological， molecular， and clinical features of noninvasive follicular thyroid neoplasm with papillary-like nuclear features versus invasive forms of follicular variant of papillary thyroid carcinoma［J］. Cancer Cytopathol， 2017， 125（5）： 323-331.
19	CHO U， METE O， KIM M H， et al. Molecular correlates and rate of lymph node metastasis of non-invasive follicular thyroid neoplasm with papillary-like nuclear features and invasive follicular variant papillary thyroid carcinoma： the impact of rigid criteria to distinguish non-invasive follicular thyroid neoplasm with papillary-like nuclear features［J］. Mod Pathol， 2017，30（6）： 810-825.
20	LEE S E， HWANG T S， CHOI Y L， et al. Molecular profiling of papillary thyroid carcinoma in Korea with a high prevalence of BRAF^V600E mutation［J］. Thyroid， 2017， 27（6）： 802-810.
21	NIKIFOROV Y E， BALOCH Z W， HODAK S P， et al. Change in diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features［J］. JAMA Oncol， 2018， 4（8）： 1125-1126.
22	CANCER GENOME ATLAS RESEARCH NETWORK. Integrated genomic characterization of papillary thyroid carcinoma［J］. Cell， 2014， 159（3）： 676-690.
23	HOWELL G M， HODAK S P， YIP L. RAS mutations in thyroid cancer［J］. Oncologist， 2013， 18（8）： 926-932.
24	魏佳，王瑶琪，孙旭，等. 甲状腺癌相关基因及其在临床诊断中应用的研究进展［J］. 吉林大学学报（医学版）， 2018， 44（4）： 880-885.
25	黑利娟，王娟红，魏威，等. 乳头状甲状腺癌患者血清和甲状腺组织中白细胞介素6水平的检测及其意义［J］. 吉林大学学报（医学版）， 2019， 45（3）： 601-605.
26	ZAJKOWSKA K， KOPCZY?SKI J， Gó?D? S， et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features： a problematic entity［J］. Endocr Connect， 2020， 9（3）： R47-R58.
27	JOHNSON D N， FURTADO L V， LONG B C， et al. Noninvasive follicular thyroid neoplasms with papillary-like nuclear features are genetically and biologically similar to adenomatous nodules and distinct from papillary thyroid carcinomas with extensive follicular growth［J］. Arch Pathol Lab Med， 2018， 142（7）： 838-850.
28	RAVELLA L， LOPEZ J， DESCOTES F， et al. Preoperative role of RAS or BRAF K601E in the guidance of surgery for indeterminate thyroid nodules［J］. World J Surg， 2020， 44（7）： 2264-2271.
29	PAULSON V A， SHIVDASANI P， ANGELL T E， et al. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features accounts for more than half of “carcinomas” harboring RAS mutations［J］. Thyroid， 2017， 27（4）： 506-511.
30	HORN S， FIGL A， RACHAKONDA P S， et al. TERT promoter mutations in familial and sporadic melanoma［J］. Science， 2013， 339（6122）： 959-961.
31	LIU R Y， XING M Z. TERT promoter mutations in thyroid cancer［J］. Endocr Relat Cancer， 2016， 23（3）： R143-R155.
32	LIU X L， BISHOP J， SHAN Y， et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers［J］. Endocr Relat Cancer， 2013， 20（4）： 603-610.
33	HYSEK M， PAULSSON J O， JATTA K， et al. Clinical routine TERT promoter mutational screening of follicular thyroid tumors of uncertain malignant potential （FT-UMPs）：a useful predictor of metastatic disease［J］.Cancers （Basel）， 2019， 11（10）： E1443.
34	PAULSSON J O， MU N N， SHABO I， et al. TERT aberrancies： a screening tool for malignancy in follicular thyroid tumours［J］. Endocr Relat Cancer， 2018， 25（7）： 723-733.
35	JETTEN A M. GLIS₁-3 transcription factors： critical roles in the regulation of multiple physiological processes and diseases［J］. Cell Mol Life Sci， 2018， 75（19）： 3473-3494.
36	NIKIFOROVA M N， NIKITSKI A V， PANEBIANCO F， et al. GLIS rearrangement is a genomic hallmark of hyalinizing trabecular tumor of the thyroid gland［J］. Thyroid， 2019， 29（2）： 161-173.
37	MARCHIò C， CRUZ PAULA ADA， GULARTE-MERIDA R， et al. PAX8-GLIS₃ gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid［J］. Mod Pathol， 2019， 32（12）： 1734-1743.
38	马晶晶，章涛. PPARγ功能与疾病关系研究进展［J］. 中国药理学通报， 2012， 28（5）： 601-604.
39	CHU Y H， SADOW P M. Noninvasive follicular thyroid neoplasm with papillary-like nuclear features （NIFTP）： Diagnostic updates and molecular advances［J］.Semin Diagn Pathol，2020，37（5）：213-218.
40	GHAFOURI-FARD S， SHIRVANI-FARSANI Z， TAHERI M. The role of microRNAs in the pathogenesis of thyroid cancer［J］. Noncoding RNA Res， 2020， 5（3）： 88-98.
41	LABOURIER E， SHIFRIN A， BUSSENIERS A E， et al. Molecular testing for miRNA， mRNA， and DNA on fine-needle aspiration improves the preoperative diagnosis of thyroid nodules with indeterminate cytology［J］. J Clin Endocrinol Metab， 2015， 100（7）： 2743-2750.
42	JACQUES C，GUILLOTIN D， FONTAINE J F，et al. DNA microarray and miRNA analyses reinforce the classification of follicular thyroid tumors［J］. J Clin Endocrinol Metab， 2013， 98（5）： E981-E989.
43	JAHANBANI I， AL-ABDALLAH A， ALI R H， et al. Discriminatory miRNAs for the management of papillary thyroid carcinoma and noninvasive follicular thyroid neoplasms with papillary-like nuclear features［J］. Thyroid， 2018， 28（3）： 319-327.
44	BORRELLI N， DENARO M， UGOLINI C， et al. miRNA expression profiling of ‘noninvasive follicular thyroid neoplasms with papillary-like nuclear features’ compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas［J］. Mod Pathol， 2017， 30（1）： 39-51.
45	DENARO M， UGOLINI C， POMA A M， et al. Differences in miRNA expression profiles between wild-type and mutated NIFTPs［J］. Endocr Relat Cancer， 2017， 24（10）： 543-553.
46	LASSALLE S， HOFMAN V， ILIE M， et al. Can the microRNA signature distinguish between thyroid tumors of uncertain malignant potential and other well-differentiated tumors of the thyroid gland？［J］. Endocr Relat Cancer， 2011， 18（5）： 579-594.
47	SHEU S Y， VOGEL E， WORM K， et al. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma［J］. Histopathology， 2010， 56（5）： 632-640.
48	DUAN H L， LIU X D， REN X Y， et al. Mutation profiles of follicular thyroid tumors by targeted sequencing［J］. Diagn Pathol， 2019， 14（1）： 39.
49	LAMBA SAINI M， WEYNAND B， RAHIER J， et al. Cyclin D1 in well differentiated thyroid tumour of uncertain malignant potential［J］. Diagn Pathol， 2015， 10： 32.
50	SALVATORE G， CHIAPPETTA G， NIKIFOROV Y E， et al. Molecular profile of hyalinizing trabecular tumours of the thyroid： high prevalence of RET/PTC rearrangements and absence of B-raf and N-ras point mutations［J］. Eur J Cancer， 2005， 41（5）： 816-821.
51	KAKUDO K. How to handle borderline/precursor thyroid tumors in management of patients with thyroid nodules［J］. Gland Surg， 2018， 7（）： S8-S18.
52	XU B， TALLINI G， SCOGNAMIGLIO T， et al. Outcome of large noninvasive follicular thyroid neoplasm with papillary-like nuclear features［J］. Thyroid， 2017， 27（4）： 512-517.
53	QIU Z L， SHEN C T， SUN Z K， et al. Distant metastases from pathologically proven benign follicular nodules of the thyroid： clinicopathological features and predictors of long-term survival［J］.Endocrine，2020，69（1）：113-125.

Tumor type	Immunohistochemistry	Genetic alteration
FT-UMP	CK19（+），Galectin-3（+）， HBME-1（+）	RAS mutation，TERT mutation PAX8/PPARγ fusion miR-221↑，miR-222↑
WDT-UMP	CK19（+），Galectin-3（+）， HBME-1（+），CD56（+），TPO（－），Cyclin D1（+）	RAS mutation miR-221↑，miR-222↑ miR-146b↑，miR-34a↑
NIFTP	PD-L1（+）	RAS mutation，THADA fusion PAX8/PPARγ fusion BRAF K601E mutation BRAFV600E（－）,TERT（-）,TP53（－） miR-152-3p↓，miR-185-5p↓ miR-574-3p↓，miR-222-3p↑
HTT	TG（+），TTF（+）， Calcitonin（－）， Ki67/MIB1（+）	PAX8/GLIS1 fusion PAX8/GLIS3 fusion RET/PTC rearrangement

[1]	Yaoyu FENG, Chenglei ZHANG, Lijuan HOU, Yifu WANG, Xiuling WU, Yunhai MA. Effect of miR-222-3p knockdown targeting PTEN on ¹³¹I radiotherapy resistance of thyroid cancer and its mechanism [J]. Journal of Jilin University(Medicine Edition), 2021, 47(3): 677-686.
[2]	Chunying ZHANG,Guangwei YIN,Mingda YOU,Hong CHEN,Yaojie HU,Yanbing LI,Chunyou CHEN. Inhibitory effects of siRNA targeting silencing TAK1 gene on proliferation and migration of thyroid cancer cells and p38 MAPK signaling pathway [J]. Journal of Jilin University(Medicine Edition), 2021, 47(1): 110-117.
[3]	DU Jinghai, CHEN Chunyou, GUO Xin, ZHANG Jing. Effects of silencing Kat5 gene on proliferation and apoptosis of thyroid papillary carcinoma cells [J]. Journal of Jilin University(Medicine Edition), 2020, 46(03): 543-550.
[4]	ZHANG Lifang, CAI Lin, WANG Yunhua, ZHANG Keshi, WU Rina. Analysis on association between selenoprotein P polymorphism and risk of papillary thyriod carcinoma [J]. Journal of Jilin University(Medicine Edition), 2020, 46(02): 383-388.
[5]	WANG Qi, SA Ri, LIN Qiuyu, ZHAO Hongguang. Protective effect of citric acid on salivary gland function in patients with differentiated thyroid cancer after first ¹³¹I treatment [J]. Journal of Jilin University(Medicine Edition), 2019, 45(04): 911-915.
[6]	HEI Lijuan, WANG Juanhong, WEI Wei, FANG Hangrong, DUAN Ying, MA Shifen, XU Junrong. Detection of interleukin-6 levels in serum and thyroid tissue of patients with papillary thyroid carcinoma and their significances [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 601-605.
[7]	. Research progress in radiofrequency ablation in treatment of papillary thyroid carcinoma [J]. Journal of Jilin University(Medicine Edition), 2019, 45(03): 731-735.
[8]	. Research progress in thyroid cancer related genes and their applications in clinical diagnosis [J]. Journal of Jilin University Medicine Edition, 2018, 44(04): 880-885.
[9]	ZHAO Zhiyan, SHENG Jindong, LIU Baoguo. Risk factors of malignant thyroid neoplasms and papillary thyroid cancer level Ⅵ lymph node metastasis [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 334-338.
[10]	. Progress research on relationship between Ki-67 and BRAF gene mutation and invasiveness of papillary thyroid carcinoma [J]. Journal of Jilin University Medicine Edition, 2016, 42(06): 1259-1262.
[11]	ZHAO Min-xue，LI Bai-wen，ZHU Lin，YE Hong-shan，TIAN Xiao-feng，WEI Liang，CAO Hong. Detection of miR-21 expression levels in carcinoma tissue and serum of patients with papillary thyroid carcinoma and its significance [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1237-1240.
[12]	SUN Qin-nuan，LI Dong-mei，YU Hui-ling，MA Hong-xi. Expressions of inflammatory factors in thyroid papillary carcinoma tissue and their clinical significances [J]. Journal of Jilin University Medicine Edition, 2014, 40(06): 1261-1265.
[13]	WU Wen-fang,QIU Jin-xu,LU Li-min,YANG Dong-yan . Characteristics of ultrasound imaging of thyroid papillary carcinoma complicated with cervical lymph node tuberculosis [J]. Journal of Jilin University Medicine Edition, 2014, 40(04): 895-897.
[14]	WANG Hai-ying,JIN Mei-shan,ZHANG Xin-mu,TIAN Zhuang,ZOU Ya-bin,GAO Jing-na,DUAN Xiu-mei,WANG Yin-ping. Expressions of survivin,galectin-3 and TPO in papillary  thyroid microcarcinoma tissue and their clinical significances  [J]. Journal of Jilin University Medicine Edition, 2014, 40(01): 150-153.
[15]	. Advanced research on relationship between iodine intake and thyriod cancer [J]. Journal of Jilin University Medicine Edition, 2013, 39(4): 847-850.

RichHTML

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 1

References

Related Articles 15

Metrics

Comments

Recommended 0